The 20 Best Chronic T-Cell Leukemia (CTCL) Doctors Near Me in Ann Arbor, MI

Dr. Lauren Smith received her undergraduate degree at the University of Michigan Honors College with highest distinction in 1992. She spent four years working in a neurogenetics laboratory at the University of San Francisco with Dr. Nelson Freimer. For the next two years she worked as a manuscript editor for Dr. Donald Klein, a psychiatrist, at Columbia University. In 1998, she began medical school at the University of Michigan. She was awarded AOA in her junior year and was president of the UM AOA Chapter the following year. She completed her residency in anatomic/clinical pathology and fellowship in hematopathology from 2002-2007. In July, 2007 she began her faculty career as an Assistant Professor at the University of Michigan and was promoted to Associate Professor in 2013. She was appointed Fellowship Director in 2013. She was appointed the Director of the Ethics Path of Excellence in the University of Michigan Medical School in 2013. She became the permanent Director of the Hematopathology Section in 2016. In addition, she serves as a Hospital Ethicist at UMHS. Dr. Smith is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). She is also highly rated in 29 other conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, and Angioimmunoblastic T-cell Lymphoma.

Dr. Burke joined the faculty in July 2014. He attended Providence College in Rhode Island where he earned his BS in Biology. Subsequently, he matriculated at the Icahn School of Medicine at Mount Sinai and earned his MD. He then completed a residency in Internal Medicine at the University of Chicago Medical Center, followed by a year serving as a Chief Resident. He recently completed his Hematology/Medical Oncology fellowship at Memorial Sloan Kettering Cancer Center in New York where his clinical and research interests focused on leukemia, particularly adult acute lymphoblastic leukemia (ALL). He performed clinical research regarding the role of asparaginase and “pediatric-inspired” therapeutic regimens in adult ALL, as well as investigating therapies that spare cytotoxic chemotherapy in older adult Philadelphia chromosome-positive ALL. Dr. Burke is focused on early phase clinical trials in acute leukemias and is treating patients with hematologic malignancies. Dr. Burke is rated as an Advanced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Aplastic Anemia, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Burke is board certified in Hematology and Medical Oncology.

Dr. Dale Bixby has been practicing hematology at the University of Michigan since 2009. He obtained his PhD in Medicinal Chemistry and Pharmaceutics at the University of Kentucky in 1999, before beginning his medical training at the University of Michigan in Ann Arbor, MI. He was a resident in the Department of Internal Medicine and then completed fellowship training in hematology and medical oncology at the University of Michigan. Dr. Bixby is currently a clinical professor and specializes in the areas of myeloid and lymphoid leukemias, myelodysplastic syndrome and bone marrow failure disorders. Dr. Bixby currently serves as the section chief of the acute leukemia program. He is also a clinical investigator in hematological malignancies. Dr. Bixby is rated as an Advanced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration. Dr. Bixby is board certified in Hematology.

The T-cell lymphomas are a heterogeneous and poorly understood group of non-Hodgkin’s lymphomas. The most common T-cell lymphoma in the United States includes a heterogeneous mix of lymphomas that lack distinguishing characteristics and, until recently, remained clinically and molecularly “unspecified”. Improved understanding of T-cell lymphoma pathogenesis and the development of novel therapeutic strategies will be needed to address this challenge and improve outcomes for patients afflicted with these aggressive lymphomas. My group made the landmark discovery that the most common T-cell lymphoma in North America is comprised of two molecularly and clinically distinct subsets. This finding has significant implications for the classification and treatment of these lymphomas. We have also demonstrated that malignant T cells remain dependent upon antigen-presenting cells within the tumor microenvironment and are developing novel therapeutic strategies targeting these cells. Many fundamental questions, including the “cell of origin”, the role of antigen-, costimulatory-, and cytokine-receptor signaling, and the contribution of myeloid-derived antigen-presenting cells in disease pathogenesis remain obscure. My laboratory uses complementary mouse models and primary T-cell lymphoma specimens (in ex vivo and patient-derived xenograft studies) to address these fundamental and clinically relevant questions. We are poised to clinically translate our laboratory-based findings into novel therapeutic strategies that we hope will improve outcomes for patients afflicted with these aggressive lymphomas. I enjoy working with a multidisciplinary team of enthusiastic collaborators who share this common goal. Dr. Wilcox is rated as an Advanced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Wilcox is board certified in Internal Medicine, Hematology, and Medical Oncology.

Dr. Pettit studied physics and magazine journalism at Syracuse University prior to earning her MD from the Chicago Medical School. She went on to complete her residency in internal medicine and fellowships in hematology/oncology and clinical pharmacology/pharmacogenomics at the University of Chicago. She has received national recognition for her research, including the Conquer Cancer Foundation/ASCO Young Investigator Award, the ASCPT Presidential Trainee Award, and selection for the ASH Clinical Research Training Institute. Dr. Pettit focuses on translational research and drug development for patients with myeloid malignancies, specifically myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia. Dr. Pettit is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). She is also highly rated in 30 other conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Splenectomy. Dr. Pettit is board certified in Medical Oncology and Hematology.

Attaphol Pawarode is a Hematologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Pawarode is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Monalisa Ghosh, MD, Assistant Professor. Dr. Ghosh graduated with honors from the University of Alabama at Birmingham with a BS in Biomedical Engineering, minor in Mathematics and Chemistry. She earned her MD from the University of Alabama School of Medicine where she also completed her residency training. Her fellowship training was completed at the NIH/NCI Medical Oncology Fellowship Program. Dr. Ghosh’s research interest is in bone marrow trans-plantation and cellular therapies to treat lymphoma. Dr. Ghosh will be seeing patients on the BMT service. Dr. Ghosh is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Follicular Lymphoma, Graft Versus Host Disease (GvHD), Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Colonoscopy.

Dr. May Chan obtained her medical degree from the State University of New York at Buffalo and was a Howard Hughes Research Scholar in 2005-2006. She completed residency training in Anatomic Pathology at Beth Israel Deaconess Medical Center in Boston, followed by a Dermatopathology fellowship at Harvard. She joined the University of Michigan in 2011 and is now a Professor of Pathology and Dermatology. She is the Interim Section Head for Dermatopathology, the Program Director for the Dermatopathology Fellowship, and the Medical Director of the Immunohistochemistry Laboratory. She also serves on the Test Development and Advisory Committee of the American Board of Pathology.Dr. Chan is an editorial board member of Modern Pathology and Journal of Cutaneous Pathology. She has a broad research interest in the areas of inflammatory skin diseases, melanocytic lesions, cutaneous adnexal neoplasms, and immunohistochemistry. She is the author/co-author of over 90 peer-reviewed publications and the book, Handbook of Direct Immunofluorescence: A Pattern-based Approach to Skin and Mucosal Biopsies.Dr. Chan is board certified in Anatomic Pathology and Dermatopathology. In addition to her primary role as a dermatopathologist, Dr. Chan retains her interest in surgical pathology including interpretation of head and neck, soft tissue, pulmonary, and endocrine cases, as well as intraoperative frozen sections. Over the years she has been invited to speak at national and international meetings hosted by the United States and Canadian Academy of Pathology (USCAP), the American Society of Dermatopathology (ASDP), the College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), the American Academy of Dermatology (AAD), the European Nail Society, and Dermpedia. Dr. Chan is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Melanoma, Basal Cell Skin Cancer, Sebaceous Adenoma, and Squamous Cell Skin Carcinoma.

Darren King is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. He has been practicing medicine for over 18 years. Dr. King is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. King is board certified in Hematology and Medical Oncology.